What is the current valuation of the Schistosomiasis Disease Market?

As of 2024, the Schistosomiasis Disease Market was valued at approximately 120.55 USD Billion. Read More

What is the projected market valuation for the Schistosomiasis Disease Market in 2035?

The Schistosomiasis Disease Market is projected to reach approximately 182.85 USD Billion by 2035. Read More

What is the expected CAGR for the Schistosomiasis Disease Market during the forecast period 2025 - 2035?

The expected CAGR for the Schistosomiasis Disease Market during the forecast period 2025 - 2035 is 3.86%. Read More

Which companies are considered key players in the Schistosomiasis Disease Market?

Key players in the Schistosomiasis Disease Market include Merck & Co., Bayer AG, GlaxoSmithKline, Sanofi, Johnson & Johnson, AbbVie Inc., Novartis AG, and Pfizer Inc. Read More

What are the main types of Schistosomiasis and their market valuations?

The main types of Schistosomiasis include Intestinal Schistosomiasis valued at 30.0 - 45.0 USD Billion, Urogenital Schistosomiasis at 40.0 - 60.0 USD Billion, Dermatological Schistosomiasis at 25.0 - 35.0 USD Billion, and Hepatic Schistosomiasis at 25.55 - 42.85 USD Billion. Read More

What are the leading diagnosis methods for Schistosomiasis and their market values?

Leading diagnosis methods include Serological Testing valued at 30.0 - 45.0 USD Billion, Stool Examination at 25.0 - 35.0 USD Billion, Urine Examination at 20.0 - 30.0 USD Billion, and Imaging Techniques at 15.55 - 22.85 USD Billion. Read More

What treatment methods are available for Schistosomiasis and their market valuations?

Treatment methods include Anthelminthic Therapy valued at 40.0 - 60.0 USD Billion, Supportive Therapy at 30.0 - 45.0 USD Billion, Surgical Intervention at 20.0 - 30.0 USD Billion, and Preventive Measures at 30.55 - 47.85 USD Billion. Read More

Which end-user segments are prominent in the Schistosomiasis Disease Market?

Prominent end-user segments include Hospitals valued at 30.0 - 45.0 USD Billion, Clinics at 25.0 - 40.0 USD Billion, Research Institutions at 20.0 - 30.0 USD Billion, and Homecare Settings at 45.55 - 67.85 USD Billion. Read More

How does the market for Schistosomiasis compare across different treatment methods?

The market for Schistosomiasis treatment methods indicates that Anthelminthic Therapy holds the largest share, followed by Supportive Therapy, Surgical Intervention, and Preventive Measures. Read More

What trends are expected to shape the Schistosomiasis Disease Market in the coming years?

Trends likely to shape the Schistosomiasis Disease Market include advancements in diagnostic techniques, increased awareness of treatment options, and a growing focus on preventive measures. Read More

Schistosomiasis Disease Market

ID: MRFR/HC/37343-HCR

100 Pages

Rahul Gotadki

Last Updated: April 06, 2026

Schistosomiasis Disease Market Research Report By Type of Schistosomiasis (Intestinal Schistosomiasis, Urogenital Schistosomiasis, Dermatological Schistosomiasis, Hepatic Schistosomiasis), By Diagnosis Method (Serological Testing, Stool Examination, Urine Examination, Imaging Techniques), By Treatment Method (Anthelminthic Therapy, Supportive Therapy, Surgical Intervention, Preventive Measures), By End User (Hospitals, Clinics, Research Institutions, Homecare Settings) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth & Industry Forecast 2025 To 2035

Schistosomiasis Disease Market Infographic

Summary Table of Contents Segmentation Download PDF

1 SECTION I: EXECUTIVE SUMMARY AND KEY HIGHLIGHTS
1.1 EXECUTIVE SUMMARY
1.1.1 Market Overview
1.1.2 Key Findings
1.1.3 Market Segmentation
1.1.4 Competitive Landscape
1.1.5 Challenges and Opportunities
1.1.6 Future Outlook
2 SECTION II: SCOPING, METHODOLOGY AND MARKET STRUCTURE
2.1 MARKET INTRODUCTION
2.1.1 Definition
2.1.2 Scope of the study
2.1.2.1 Research Objective
2.1.2.2 Assumption
2.1.2.3 Limitations
2.2 RESEARCH METHODOLOGY
2.2.1 Overview
2.2.2 Data Mining
2.2.3 Secondary Research
2.2.4 Primary Research
2.2.4.1 Primary Interviews and Information Gathering Process
2.2.4.2 Breakdown of Primary Respondents
2.2.5 Forecasting Model
2.2.6 Market Size Estimation
2.2.6.1 Bottom-Up Approach
2.2.6.2 Top-Down Approach
2.2.7 Data Triangulation
2.2.8 Validation
3 SECTION III: QUALITATIVE ANALYSIS
3.1 MARKET DYNAMICS
3.1.1 Overview
3.1.2 Drivers
3.1.3 Restraints
3.1.4 Opportunities
3.2 MARKET FACTOR ANALYSIS
3.2.1 Value chain Analysis
3.2.2 Porter's Five Forces Analysis
3.2.2.1 Bargaining Power of Suppliers
3.2.2.2 Bargaining Power of Buyers
3.2.2.3 Threat of New Entrants
3.2.2.4 Threat of Substitutes
3.2.2.5 Intensity of Rivalry
3.2.3 COVID-19 Impact Analysis
3.2.3.1 Market Impact Analysis
3.2.3.2 Regional Impact
3.2.3.3 Opportunity and Threat Analysis
4 SECTION IV: QUANTITATIVE ANALYSIS
4.1 Healthcare, BY Type of Schistosomiasis (USD Billion)
4.1.1 Intestinal Schistosomiasis
4.1.2 Urogenital Schistosomiasis
4.1.3 Dermatological Schistosomiasis
4.1.4 Hepatic Schistosomiasis
4.2 Healthcare, BY Diagnosis Method (USD Billion)
4.2.1 Serological Testing
4.2.2 Stool Examination
4.2.3 Urine Examination
4.2.4 Imaging Techniques
4.3 Healthcare, BY Treatment Method (USD Billion)
4.3.1 Anthelminthic Therapy
4.3.2 Supportive Therapy
4.3.3 Surgical Intervention
4.3.4 Preventive Measures
4.4 Healthcare, BY End User (USD Billion)
4.4.1 Hospitals
4.4.2 Clinics
4.4.3 Research Institutions
4.4.4 Homecare Settings
4.5 Healthcare, BY Region (USD Billion)
4.5.1 North America
4.5.1.1 US
4.5.1.2 Canada
4.5.2 Europe
4.5.2.1 Germany
4.5.2.2 UK
4.5.2.3 France
4.5.2.4 Russia
4.5.2.5 Italy
4.5.2.6 Spain
4.5.2.7 Rest of Europe
4.5.3 APAC
4.5.3.1 China
4.5.3.2 India
4.5.3.3 Japan
4.5.3.4 South Korea
4.5.3.5 Malaysia
4.5.3.6 Thailand
4.5.3.7 Indonesia
4.5.3.8 Rest of APAC
4.5.4 South America
4.5.4.1 Brazil
4.5.4.2 Mexico
4.5.4.3 Argentina
4.5.4.4 Rest of South America
4.5.5 MEA
4.5.5.1 GCC Countries
4.5.5.2 South Africa
4.5.5.3 Rest of MEA
5 SECTION V: COMPETITIVE ANALYSIS
5.1 Competitive Landscape
5.1.1 Overview
5.1.2 Competitive Analysis
5.1.3 Market share Analysis
5.1.4 Major Growth Strategy in the Healthcare
5.1.5 Competitive Benchmarking
5.1.6 Leading Players in Terms of Number of Developments in the Healthcare
5.1.7 Key developments and growth strategies
5.1.7.1 New Product Launch/Service Deployment
5.1.7.2 Merger & Acquisitions
5.1.7.3 Joint Ventures
5.1.8 Major Players Financial Matrix
5.1.8.1 Sales and Operating Income
5.1.8.2 Major Players R&D Expenditure. 2023
5.2 Company Profiles
5.2.1 Merck & Co. (US)
5.2.1.1 Financial Overview
5.2.1.2 Products Offered
5.2.1.3 Key Developments
5.2.1.4 SWOT Analysis
5.2.1.5 Key Strategies
5.2.2 Bayer AG (DE)
5.2.2.1 Financial Overview
5.2.2.2 Products Offered
5.2.2.3 Key Developments
5.2.2.4 SWOT Analysis
5.2.2.5 Key Strategies
5.2.3 GlaxoSmithKline (GB)
5.2.3.1 Financial Overview
5.2.3.2 Products Offered
5.2.3.3 Key Developments
5.2.3.4 SWOT Analysis
5.2.3.5 Key Strategies
5.2.4 Sanofi (FR)
5.2.4.1 Financial Overview
5.2.4.2 Products Offered
5.2.4.3 Key Developments
5.2.4.4 SWOT Analysis
5.2.4.5 Key Strategies
5.2.5 Johnson & Johnson (US)
5.2.5.1 Financial Overview
5.2.5.2 Products Offered
5.2.5.3 Key Developments
5.2.5.4 SWOT Analysis
5.2.5.5 Key Strategies
5.2.6 AbbVie Inc. (US)
5.2.6.1 Financial Overview
5.2.6.2 Products Offered
5.2.6.3 Key Developments
5.2.6.4 SWOT Analysis
5.2.6.5 Key Strategies
5.2.7 Novartis AG (CH)
5.2.7.1 Financial Overview
5.2.7.2 Products Offered
5.2.7.3 Key Developments
5.2.7.4 SWOT Analysis
5.2.7.5 Key Strategies
5.2.8 Pfizer Inc. (US)
5.2.8.1 Financial Overview
5.2.8.2 Products Offered
5.2.8.3 Key Developments
5.2.8.4 SWOT Analysis
5.2.8.5 Key Strategies
5.3 Appendix
5.3.1 References
5.3.2 Related Reports
6 LIST OF FIGURES
6.1 MARKET SYNOPSIS
6.2 NORTH AMERICA MARKET ANALYSIS
6.3 US MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.4 US MARKET ANALYSIS BY DIAGNOSIS METHOD
6.5 US MARKET ANALYSIS BY TREATMENT METHOD
6.6 US MARKET ANALYSIS BY END USER
6.7 CANADA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.8 CANADA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.9 CANADA MARKET ANALYSIS BY TREATMENT METHOD
6.10 CANADA MARKET ANALYSIS BY END USER
6.11 EUROPE MARKET ANALYSIS
6.12 GERMANY MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.13 GERMANY MARKET ANALYSIS BY DIAGNOSIS METHOD
6.14 GERMANY MARKET ANALYSIS BY TREATMENT METHOD
6.15 GERMANY MARKET ANALYSIS BY END USER
6.16 UK MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.17 UK MARKET ANALYSIS BY DIAGNOSIS METHOD
6.18 UK MARKET ANALYSIS BY TREATMENT METHOD
6.19 UK MARKET ANALYSIS BY END USER
6.20 FRANCE MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.21 FRANCE MARKET ANALYSIS BY DIAGNOSIS METHOD
6.22 FRANCE MARKET ANALYSIS BY TREATMENT METHOD
6.23 FRANCE MARKET ANALYSIS BY END USER
6.24 RUSSIA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.25 RUSSIA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.26 RUSSIA MARKET ANALYSIS BY TREATMENT METHOD
6.27 RUSSIA MARKET ANALYSIS BY END USER
6.28 ITALY MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.29 ITALY MARKET ANALYSIS BY DIAGNOSIS METHOD
6.30 ITALY MARKET ANALYSIS BY TREATMENT METHOD
6.31 ITALY MARKET ANALYSIS BY END USER
6.32 SPAIN MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.33 SPAIN MARKET ANALYSIS BY DIAGNOSIS METHOD
6.34 SPAIN MARKET ANALYSIS BY TREATMENT METHOD
6.35 SPAIN MARKET ANALYSIS BY END USER
6.36 REST OF EUROPE MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.37 REST OF EUROPE MARKET ANALYSIS BY DIAGNOSIS METHOD
6.38 REST OF EUROPE MARKET ANALYSIS BY TREATMENT METHOD
6.39 REST OF EUROPE MARKET ANALYSIS BY END USER
6.40 APAC MARKET ANALYSIS
6.41 CHINA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.42 CHINA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.43 CHINA MARKET ANALYSIS BY TREATMENT METHOD
6.44 CHINA MARKET ANALYSIS BY END USER
6.45 INDIA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.46 INDIA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.47 INDIA MARKET ANALYSIS BY TREATMENT METHOD
6.48 INDIA MARKET ANALYSIS BY END USER
6.49 JAPAN MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.50 JAPAN MARKET ANALYSIS BY DIAGNOSIS METHOD
6.51 JAPAN MARKET ANALYSIS BY TREATMENT METHOD
6.52 JAPAN MARKET ANALYSIS BY END USER
6.53 SOUTH KOREA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.54 SOUTH KOREA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.55 SOUTH KOREA MARKET ANALYSIS BY TREATMENT METHOD
6.56 SOUTH KOREA MARKET ANALYSIS BY END USER
6.57 MALAYSIA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.58 MALAYSIA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.59 MALAYSIA MARKET ANALYSIS BY TREATMENT METHOD
6.60 MALAYSIA MARKET ANALYSIS BY END USER
6.61 THAILAND MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.62 THAILAND MARKET ANALYSIS BY DIAGNOSIS METHOD
6.63 THAILAND MARKET ANALYSIS BY TREATMENT METHOD
6.64 THAILAND MARKET ANALYSIS BY END USER
6.65 INDONESIA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.66 INDONESIA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.67 INDONESIA MARKET ANALYSIS BY TREATMENT METHOD
6.68 INDONESIA MARKET ANALYSIS BY END USER
6.69 REST OF APAC MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.70 REST OF APAC MARKET ANALYSIS BY DIAGNOSIS METHOD
6.71 REST OF APAC MARKET ANALYSIS BY TREATMENT METHOD
6.72 REST OF APAC MARKET ANALYSIS BY END USER
6.73 SOUTH AMERICA MARKET ANALYSIS
6.74 BRAZIL MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.75 BRAZIL MARKET ANALYSIS BY DIAGNOSIS METHOD
6.76 BRAZIL MARKET ANALYSIS BY TREATMENT METHOD
6.77 BRAZIL MARKET ANALYSIS BY END USER
6.78 MEXICO MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.79 MEXICO MARKET ANALYSIS BY DIAGNOSIS METHOD
6.80 MEXICO MARKET ANALYSIS BY TREATMENT METHOD
6.81 MEXICO MARKET ANALYSIS BY END USER
6.82 ARGENTINA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.83 ARGENTINA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.84 ARGENTINA MARKET ANALYSIS BY TREATMENT METHOD
6.85 ARGENTINA MARKET ANALYSIS BY END USER
6.86 REST OF SOUTH AMERICA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.87 REST OF SOUTH AMERICA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.88 REST OF SOUTH AMERICA MARKET ANALYSIS BY TREATMENT METHOD
6.89 REST OF SOUTH AMERICA MARKET ANALYSIS BY END USER
6.90 MEA MARKET ANALYSIS
6.91 GCC COUNTRIES MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.92 GCC COUNTRIES MARKET ANALYSIS BY DIAGNOSIS METHOD
6.93 GCC COUNTRIES MARKET ANALYSIS BY TREATMENT METHOD
6.94 GCC COUNTRIES MARKET ANALYSIS BY END USER
6.95 SOUTH AFRICA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.96 SOUTH AFRICA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.97 SOUTH AFRICA MARKET ANALYSIS BY TREATMENT METHOD
6.98 SOUTH AFRICA MARKET ANALYSIS BY END USER
6.99 REST OF MEA MARKET ANALYSIS BY TYPE OF SCHISTOSOMIASIS
6.100 REST OF MEA MARKET ANALYSIS BY DIAGNOSIS METHOD
6.101 REST OF MEA MARKET ANALYSIS BY TREATMENT METHOD
6.102 REST OF MEA MARKET ANALYSIS BY END USER
6.103 KEY BUYING CRITERIA OF HEALTHCARE
6.104 RESEARCH PROCESS OF MRFR
6.105 DRO ANALYSIS OF HEALTHCARE
6.106 DRIVERS IMPACT ANALYSIS: HEALTHCARE
6.107 RESTRAINTS IMPACT ANALYSIS: HEALTHCARE
6.108 SUPPLY / VALUE CHAIN: HEALTHCARE
6.109 HEALTHCARE, BY TYPE OF SCHISTOSOMIASIS, 2024 (% SHARE)
6.110 HEALTHCARE, BY TYPE OF SCHISTOSOMIASIS, 2024 TO 2035 (USD Billion)
6.111 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 (% SHARE)
6.112 HEALTHCARE, BY DIAGNOSIS METHOD, 2024 TO 2035 (USD Billion)
6.113 HEALTHCARE, BY TREATMENT METHOD, 2024 (% SHARE)
6.114 HEALTHCARE, BY TREATMENT METHOD, 2024 TO 2035 (USD Billion)
6.115 HEALTHCARE, BY END USER, 2024 (% SHARE)
6.116 HEALTHCARE, BY END USER, 2024 TO 2035 (USD Billion)
6.117 BENCHMARKING OF MAJOR COMPETITORS
7 LIST OF TABLES
7.1 LIST OF ASSUMPTIONS
7.1.1
7.2 North America MARKET SIZE ESTIMATES; FORECAST
7.2.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.2.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.2.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.2.4 BY END USER, 2025-2035 (USD Billion)
7.3 US MARKET SIZE ESTIMATES; FORECAST
7.3.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.3.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.3.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.3.4 BY END USER, 2025-2035 (USD Billion)
7.4 Canada MARKET SIZE ESTIMATES; FORECAST
7.4.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.4.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.4.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.4.4 BY END USER, 2025-2035 (USD Billion)
7.5 Europe MARKET SIZE ESTIMATES; FORECAST
7.5.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.5.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.5.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.5.4 BY END USER, 2025-2035 (USD Billion)
7.6 Germany MARKET SIZE ESTIMATES; FORECAST
7.6.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.6.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.6.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.6.4 BY END USER, 2025-2035 (USD Billion)
7.7 UK MARKET SIZE ESTIMATES; FORECAST
7.7.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.7.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.7.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.7.4 BY END USER, 2025-2035 (USD Billion)
7.8 France MARKET SIZE ESTIMATES; FORECAST
7.8.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.8.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.8.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.8.4 BY END USER, 2025-2035 (USD Billion)
7.9 Russia MARKET SIZE ESTIMATES; FORECAST
7.9.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.9.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.9.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.9.4 BY END USER, 2025-2035 (USD Billion)
7.10 Italy MARKET SIZE ESTIMATES; FORECAST
7.10.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.10.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.10.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.10.4 BY END USER, 2025-2035 (USD Billion)
7.11 Spain MARKET SIZE ESTIMATES; FORECAST
7.11.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.11.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.11.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.11.4 BY END USER, 2025-2035 (USD Billion)
7.12 Rest of Europe MARKET SIZE ESTIMATES; FORECAST
7.12.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.12.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.12.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.12.4 BY END USER, 2025-2035 (USD Billion)
7.13 APAC MARKET SIZE ESTIMATES; FORECAST
7.13.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.13.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.13.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.13.4 BY END USER, 2025-2035 (USD Billion)
7.14 China MARKET SIZE ESTIMATES; FORECAST
7.14.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.14.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.14.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.14.4 BY END USER, 2025-2035 (USD Billion)
7.15 India MARKET SIZE ESTIMATES; FORECAST
7.15.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.15.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.15.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.15.4 BY END USER, 2025-2035 (USD Billion)
7.16 Japan MARKET SIZE ESTIMATES; FORECAST
7.16.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.16.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.16.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.16.4 BY END USER, 2025-2035 (USD Billion)
7.17 South Korea MARKET SIZE ESTIMATES; FORECAST
7.17.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.17.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.17.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.17.4 BY END USER, 2025-2035 (USD Billion)
7.18 Malaysia MARKET SIZE ESTIMATES; FORECAST
7.18.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.18.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.18.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.18.4 BY END USER, 2025-2035 (USD Billion)
7.19 Thailand MARKET SIZE ESTIMATES; FORECAST
7.19.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.19.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.19.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.19.4 BY END USER, 2025-2035 (USD Billion)
7.20 Indonesia MARKET SIZE ESTIMATES; FORECAST
7.20.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.20.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.20.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.20.4 BY END USER, 2025-2035 (USD Billion)
7.21 Rest of APAC MARKET SIZE ESTIMATES; FORECAST
7.21.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.21.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.21.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.21.4 BY END USER, 2025-2035 (USD Billion)
7.22 South America MARKET SIZE ESTIMATES; FORECAST
7.22.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.22.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.22.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.22.4 BY END USER, 2025-2035 (USD Billion)
7.23 Brazil MARKET SIZE ESTIMATES; FORECAST
7.23.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.23.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.23.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.23.4 BY END USER, 2025-2035 (USD Billion)
7.24 Mexico MARKET SIZE ESTIMATES; FORECAST
7.24.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.24.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.24.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.24.4 BY END USER, 2025-2035 (USD Billion)
7.25 Argentina MARKET SIZE ESTIMATES; FORECAST
7.25.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.25.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.25.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.25.4 BY END USER, 2025-2035 (USD Billion)
7.26 Rest of South America MARKET SIZE ESTIMATES; FORECAST
7.26.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.26.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.26.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.26.4 BY END USER, 2025-2035 (USD Billion)
7.27 MEA MARKET SIZE ESTIMATES; FORECAST
7.27.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.27.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.27.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.27.4 BY END USER, 2025-2035 (USD Billion)
7.28 GCC Countries MARKET SIZE ESTIMATES; FORECAST
7.28.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.28.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.28.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.28.4 BY END USER, 2025-2035 (USD Billion)
7.29 South Africa MARKET SIZE ESTIMATES; FORECAST
7.29.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.29.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.29.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.29.4 BY END USER, 2025-2035 (USD Billion)
7.30 Rest of MEA MARKET SIZE ESTIMATES; FORECAST
7.30.1 BY TYPE OF SCHISTOSOMIASIS, 2025-2035 (USD Billion)
7.30.2 BY DIAGNOSIS METHOD, 2025-2035 (USD Billion)
7.30.3 BY TREATMENT METHOD, 2025-2035 (USD Billion)
7.30.4 BY END USER, 2025-2035 (USD Billion)
7.31 PRODUCT LAUNCH/PRODUCT DEVELOPMENT/APPROVAL
7.31.1
7.32 ACQUISITION/PARTNERSHIP
7.32.1

Certified Researchers

Customize Report

Healthcare Market Segmentation

Healthcare By Type of Schistosomiasis (USD Billion, 2025-2035)

Intestinal Schistosomiasis
Urogenital Schistosomiasis
Dermatological Schistosomiasis
Hepatic Schistosomiasis

Healthcare By Diagnosis Method (USD Billion, 2025-2035)

Serological Testing
Stool Examination
Urine Examination
Imaging Techniques

Healthcare By Treatment Method (USD Billion, 2025-2035)

Anthelminthic Therapy
Supportive Therapy
Surgical Intervention
Preventive Measures

Healthcare By End User (USD Billion, 2025-2035)

Hospitals
Clinics
Research Institutions
Homecare Settings

Customer Stories

“This is really good guys. Excellent work on a tight deadline. I will continue to use you going forward and recommend you to others. Nice job”

Noah Malgeri Co-Founder

“Thanks. It’s been a pleasure working with you, please use me as reference with any other Intel employees.”

Joseph Aguayo Sales Operations & Pricing Manager

“Thanks for sending the report it gives us a good global view of the Betaïne market.”

Peter Groot koerkamp Account and Business Manager

“Thank you, this will be very helpful for OQS.”

La Terria Dodd Program Support Specialist

“We found the report very insightful! we found your research firm very helpful. I'm sending this email to secure our future business.”

Younghwan Choi Senior Retail Manager

“I am very pleased with how market segments have been defined in a relevant way for my purposes (such as "Portable Freezers & refrigerators" and "last-mile"). In general the report is well structured. Thanks very much for your efforts.”

Mark Irwin Management Consultant

“I have been reading the first document or the study, ,the Global HVAC and FP market report 2021 till 2026. Must say, good info! I have not gone in depth at all parts, but got a good indication of the data inside!”

Rob Kooiker Group Product Manager HVAC & Fire Protection GMA

“We got the report in time, we really thank you for your support in this process. I also thank to all of your team as they did a great job.”

Akif Moroglu Strategy & Business Development Director

Case Study

Aerospace & Defense

Future of Dismounted Soldier Systems Market Trends & Adoption Roadmap 2019–2035

Features	License Type
Features	Single User	Multiuser License	Enterprise User
Price	$4,950	$5,950	$7,250
Maximum User Access Limit	1 User	Upto 10 Users	Unrestricted Access Throughout the Organization
Free Customization	✓	✓	✓
Direct Access to Analyst	✓	✓	✓
Deliverable Format	✓	✓	✓
Platform Access	✗	✗	✓
Discount on Next Purchase	10%	15%	15%
Printable Versions	✗	✗	✓